CureVac Frames Comeback With Dutch Biotech Buy
Adopting Neoantigen Approach For Cancer Vaccines
The German firm is buying Frame Cancer Therapeutics in a deal valued at €32m, with CEO Franz-Werner Haas claiming that it will help the firm in its search for promising neoantigens for its mRNA cancer vaccine programs.
